Shares of Repros Therapeutics (RPRX) rocket up 13% in AH trading after the firm announces data from a recent study showed a does of its Androxal treatment displays similar efficacy to similar FDA-approved testosterone-boosting gels.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs